Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs

Abstract Introduction This open-label study evaluated the immunogenicity, safety, and efficacy of sarilumab monotherapy in patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response or intolerance to prior conventional synthetic disease-modifying antirheumatic drugs....

Full description

Bibliographic Details
Main Authors: Alvin F. Wells, Janie Parrino, Erin K. Mangan, Anne Paccaly, Yong Lin, Christine Xu, Chunpeng Fan, Neil M. H. Graham, Hubert van Hoogstraten, Albert Torri
Format: Article
Language:English
Published: Adis, Springer Healthcare 2019-05-01
Series:Rheumatology and Therapy
Subjects:
Arthritis
Biological DMARDs
Rheumatoid arthritis
Online Access:http://link.springer.com/article/10.1007/s40744-019-0157-3

Internet

http://link.springer.com/article/10.1007/s40744-019-0157-3

Similar Items